(lp0
S'Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today Motley Fool - Feb 21, 2017 Momenta Pharmaceuticals  stock is down 15.4% at 11:50 a.m. EST Tuesday after the company announced on Friday after the closing bell that its three-times-weekly version of Glatopa is unlikely to be approved this quarter due to a&nbsp;...Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat - Madison.com'
p1
aS'Why Momenta Pharmaceuticals, Inc. Jumped Higher Today Motley Fool - Oct 11, 2016 Before then, it seems likely Momenta will try and partner M923 . Last month, Momenta announced that it will regain rights to the drug from Shire.A Compelling Risk/Reward Seen In Momenta Pharmaceuticals - BenzingaMomenta Pharmaceuticals  Stock Surges, Barclays Upgrades - TheStreet.com'
p2
aS'Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License ... GlobeNewswire  - Feb 17, 2017 CAMBRIDGE, Mass., Feb. 17, 2017  -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable&nbsp;...Momenta Pharmaceuticals, Inc.  Scheduled to Post Quarterly Earnings on ... - Sports Perspectives'
p3
aS'Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today Motley Fool - Jan 31, 2017 Shares of Momenta Pharmaceuticals  are up over 20% at 12:28 p.m. EST after the company announced that the U.S.Why Analysts Are Chasing Momenta Pharmaceuticals Even Higher - 24/7 Wall St.'
p4
aS'Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and ... GlobeNewswire  - Nov 2, 2016 CAMBRIDGE, Mass., Nov. 02, 2016  -- Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Scott M.Mylan, Momenta move ahead in trial for rheumatoid arthritis drug - Pittsburgh Business Times'
p5
aS"Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead? Motley Fool - Aug 9, 2016 While the report included sales of Momenta's and partner Novartis AG's  Glatopa, the generic version of Teva Pharmaceutical Industries'  once-daily Copaxone, investors should focus on the potential approval of the generic&nbsp;..."
p6
aS"Tuesday's Market Insights: DryShips Inc. , Momenta Pharmaceuticals, Inc ... Smarter Analyst - Feb 21, 2017 Momenta Pharmaceuticals, Inc.  shares are trading down 14% after the complex pharmaceutical company announced that a warning letter had been delivered from the FDA to Pfizer, Sandoz's contracted manufacturer for Glatopa, a drug&nbsp;..."
p7
aS'A Somewhat Murky Outlook For Momenta Pharmaceuticals Seeking Alpha - Dec 28, 2016 Although I have made some good gains from Momenta Pharmaceuticals over the past few months, it is one of the murkiest companies I follow in the biotech space.'
p8
aS'Momenta Pharmaceuticals Inc.  Moves Lower on Volume Spike for March 17 Equities.com - Mar 17, 2017 Momenta Pharmaceuticals Inc.  traded on unusually high volume on Mar. 17, as the stock lost 0.72% to close at $13.75.EPS Projection Of Momenta Pharmaceuticals, Inc.  At $0.28 - RealistInvestor.comNext Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc.  - Fiscal Standard'
p9
aS"Momenta Pharma shares halted as drug application hits speed bump MarketWatch - Feb 17, 2017 Momenta Pharmaceuticals Inc. MNTA, -0.72% were halted in the extended session Friday after the biotech company said a supplier's compliance issue could delay approval of a higher dose of one of its multiple sclerosis drugs.Momenta halted after noting compliance issue in drug application - Seeking Alpha"
p10
a.